NTLA241018C35000
- 0.04
- -0.01-20.00%
Intellia Therapeutics Newsroom
BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Truist Financial Initiates a Buy Rating on Intellia Therapeutics (NTLA)
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
Buy Rating on Intellia Therapeutics Backed by Promising Phase 1 Study and Upcoming Data Presentation
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
Intellia Therapeutics (NTLA) Receives a Buy From RBC Capital
JonesTrading Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $41
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $64
Intellia Therapeutics Is Maintained at Buy by Stifel
Intellia Therapeutics Analyst Ratings
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Intellia Therapeutics Analyst Ratings
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk